Marc‐Steffen Raab

2.4k total citations · 1 hit paper
50 papers, 1.2k citations indexed

About

Marc‐Steffen Raab is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Marc‐Steffen Raab has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Molecular Biology and 23 papers in Oncology. Recurrent topics in Marc‐Steffen Raab's work include Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (9 papers) and CAR-T cell therapy research (7 papers). Marc‐Steffen Raab is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (9 papers) and CAR-T cell therapy research (7 papers). Marc‐Steffen Raab collaborates with scholars based in Germany, United States and Belgium. Marc‐Steffen Raab's co-authors include Christopher E. Rudd, Kartik Prasad, Lewis C. Cantley, Hartmut Goldschmidt, Brian Duckworth, Steven E. Shoelson, Ying Cai, Ottmar Janßen, Rosana Kapeller and Jens Hillengaß and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Marc‐Steffen Raab

49 papers receiving 1.2k citations

Hit Papers

The pre-existing T cell landscape determines the response... 2023 2026 2024 2025 2023 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
    2023 131 citations Mirco Friedrich, Paola Neri et al. Cancer Cell profile →

Peers

Marc‐Steffen Raab
Bonnie K. Arendt United States
Lars Sternås United States
Mark Klinger United States
Geneviève Fiol France
Robert Wasserman United States
Gregory Ahmann United States
Jörg Westermann Germany
Csaba Bödör Hungary
Rogier M. Reijmers Netherlands
Gary Calandra United States
Bonnie K. Arendt United States
Marc‐Steffen Raab
Citations per year, relative to Marc‐Steffen Raab Marc‐Steffen Raab (= 1×) peers Bonnie K. Arendt

Countries citing papers authored by Marc‐Steffen Raab

Since Specialization
Citations

This map shows the geographic impact of Marc‐Steffen Raab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc‐Steffen Raab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc‐Steffen Raab more than expected).

Fields of papers citing papers by Marc‐Steffen Raab

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc‐Steffen Raab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc‐Steffen Raab. The network helps show where Marc‐Steffen Raab may publish in the future.

Co-authorship network of co-authors of Marc‐Steffen Raab

This figure shows the co-authorship network connecting the top 25 collaborators of Marc‐Steffen Raab. A scholar is included among the top collaborators of Marc‐Steffen Raab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc‐Steffen Raab. Marc‐Steffen Raab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weinhold, Niels, Sandra Sauer, Marc‐Steffen Raab, et al.. (2025). Advanced Automated Model for Robust Bone Marrow Segmentation in Whole-body MRI. Academic Radiology. 32(5). 2824–2835. 1 indexed citations
2.
Friedrich, Mirco, Paola Neri, Simon Steiger, et al.. (2023). The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 41(4). 711–725.e6. 131 indexed citations breakdown →
3.
Kauer, Joseph, Katharina Kriegsmann, Niels Weinhold, et al.. (2023). Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematological Oncology. 41(3). 453–462. 5 indexed citations
4.
Dapunt, Ulrike, Joachim Wiskemann, Dirk Jäger, et al.. (2023). A precision‐based exercise program for patients with multiple myeloma. European Journal Of Haematology. 111(6). 930–937. 2 indexed citations
5.
Sauer, Sandra, Katharina Kriegsmann, Cathleen Nientiedt, et al.. (2023). Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Transfusion Medicine and Hemotherapy. 50(5). 371–381. 4 indexed citations
6.
Kilian, Michael, Sebastian Uhrig, Alexander Brobeil, et al.. (2022). IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. Journal for ImmunoTherapy of Cancer. 10(10). e005815–e005815. 5 indexed citations
7.
Wei, Lanying, Subbaiah Chary Nimmagadda, Anja Baumann, et al.. (2022). Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells. Frontiers in Oncology. 12. 874325–874325. 7 indexed citations
8.
9.
John, Lukas, Alexandra M. Poos, Stephan M. Tirier, et al.. (2021). The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients - from Sub-Clonal Architecture to the Immune Microenvironment. Blood. 138(Supplement 1). 729–729. 3 indexed citations
10.
11.
Sachpekidis, Christos, Maximilian Merz, Marc‐Steffen Raab, et al.. (2021). The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Research. 11(1). 100–100. 18 indexed citations
12.
Seckinger, Anja, Jens Hillengaß, Martina Emde, et al.. (2018). CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Frontiers in Immunology. 9. 1676–1676. 32 indexed citations
13.
Breitkreutz, Iris, Marc‐Steffen Raab, & Hartmut Goldschmidt. (2018). Primärtherapie beim Multiplen Myelom. Der Internist. 60(1). 23–33. 1 indexed citations
14.
Yong, Kwee, Michel Delforge, Christoph Driessen, et al.. (2015). MULTIPLE MYELOMA MANAGEMENT: OUTCOMES IN REAL-WORLD PRACTICE. Haematologica. 100. 252–253. 1 indexed citations
15.
Raab, Marc‐Steffen, Michèle Cavo, Michel Delforge, et al.. (2015). MULTIPLE MYELOMA MANAGEMENT: PRACTICE PATTERNS ACROSS EUROPE. Haematologica. 100. 251–252. 3 indexed citations
16.
Schmitt, Stefan, Thomas Hielscher, Claudia D. Baldus, et al.. (2013). Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation. International Journal of Hematology. 97(6). 765–772. 2 indexed citations
17.
18.
Breitkreutz, Iris, H M Lokhorst, Marc‐Steffen Raab, et al.. (2007). Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 21(6). 1294–1299. 40 indexed citations
19.
Raab, Marc‐Steffen, Iris Breitkreutz, & Kenneth C. Anderson. (2007). Targeted treatments to improve stem cell outcome: old and new drugs. Bone Marrow Transplantation. 40(12). 1129–1137. 4 indexed citations
20.
Raab, Marc‐Steffen, F. W. Cremer, Iris Breitkreutz, et al.. (2005). Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Annals of Oncology. 16(4). 611–617. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bonnie K. Arendt Breakdown of academic impact, for papers by Lars Sternås Breakdown of academic impact, for papers by Mark Klinger Breakdown of academic impact, for papers by Geneviève Fiol Breakdown of academic impact, for papers by Robert Wasserman Breakdown of academic impact, for papers by Gregory Ahmann Breakdown of academic impact, for papers by Jörg Westermann Breakdown of academic impact, for papers by Csaba Bödör Breakdown of academic impact, for papers by Rogier M. Reijmers Breakdown of academic impact, for papers by Gary Calandra
Rankless by CCL
2026